Consistent with its role as a versatile RNA helicase, DDX5 has emerged as a multifunctional oncogenic driver in both solid and hematologic malignancies, integrating upstream signaling inputs with downstream transcriptional and post-transcriptional programs that sustain tumor growth, survival, and therapy resistance. This evidence concerns the gene DDX5 and hematologic disorder.